Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:42 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1591
Shown on this page
12
Current sort
Recently updated
Campus scope
Ohio State University Wexner Medical Center, Columbus, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Ohio State University Wexner Medical Center, Columbus, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 637–648 of 1,591 matching trials with a site at Ohio State University Wexner Medical Center, Columbus, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433
Site status not listed — check the official record
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting Phase 2 Interventional

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT04115631
Site status not listed — check the official record
View directory record Official record
Conditions
Liver Lymphoma, Mantle Cell Lymphoma
Interventions
Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
504
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
Site status not listed — check the official record
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ultrasound for Socket Healing Evaluation

NCT06017193
Site status not listed — check the official record
View directory record Official record
Conditions
Healing Wound, Alveolar; Wound, Alveolar Bone Loss, Image, Dent Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Not yet recruiting No phase listed Observational

Outcomes of Different Bone Graft Combinations for Maxillary Sinus Augmentation Procedure

NCT07512011
Site status not listed — check the official record
View directory record Official record
Conditions
Bone Grafting, Sinus Lifting
Interventions
Bone grafting on both sides
Device
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
Site status not listed — check the official record
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting Phase 2 Interventional

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib Fosmecarbil, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
35
States / cities
Sun City, Arizona • Chula Vista, California • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Recruiting Phase 2 Interventional

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

NCT07048808
Status at this site: Recruiting
View directory record Official record
Conditions
Refractory Angina, Coronary Artery Disease
Interventions
XC001, Sham (No Treatment)
Combination Product
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Recruiting Phase 1 Interventional

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

NCT04633239
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Olaparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Active, not recruiting Phase 3 Interventional Results available

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828
Site status not listed — check the official record
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Recruiting No phase listed Observational

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

NCT06486454
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
Interventions
HistoSonics Edison System
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
33
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST
Recruiting Not applicable Interventional

Humidity in Incubators for Tiny Infants

NCT06399861
Status at this site: Recruiting
View directory record Official record
Conditions
Extremely Premature Infant
Interventions
Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10, Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 28
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Days to 1 Day
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 1, 2026, 6:42 PM EST

About this Ohio State University Wexner Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.